Autolus Therapeutics (NASDAQ:AUTL) Shares Down 5.6% – Here’s What Happened

Autolus Therapeutics plc (NASDAQ:AUTL)’s stock price was down 5.6% during mid-day trading on Thursday . The company traded as low as $2.20 and last traded at $2.20. Approximately 210,469 shares changed hands during mid-day trading, a decline of 80% from the average daily volume of 1,070,862 shares. The stock had previously closed at $2.33.

Analysts Set New Price Targets

A number of equities analysts have commented on AUTL shares. Redburn Atlantic upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 target price for the company in a report on Friday, November 15th. The Goldman Sachs Group upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $7.00 to $7.60 in a research note on Monday, November 18th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $10.00 price target on shares of Autolus Therapeutics in a research note on Monday. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $10.40.

Autolus Therapeutics Trading Down 6.2 %

The stock has a market capitalization of $581.41 million, a price-to-earnings ratio of -1.81 and a beta of 2.05. The firm has a 50-day moving average of $2.76 and a 200-day moving average of $3.58.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same period in the previous year, the business posted ($0.26) EPS. On average, equities research analysts anticipate that Autolus Therapeutics plc will post -0.94 EPS for the current year.

Institutional Investors Weigh In On Autolus Therapeutics

Several hedge funds have recently modified their holdings of AUTL. Wellington Management Group LLP grew its holdings in Autolus Therapeutics by 35.4% in the third quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company’s stock valued at $87,919,000 after purchasing an additional 6,330,392 shares during the period. FMR LLC lifted its position in shares of Autolus Therapeutics by 44.6% during the 3rd quarter. FMR LLC now owns 17,773,873 shares of the company’s stock valued at $64,519,000 after buying an additional 5,478,706 shares in the last quarter. Great Point Partners LLC grew its stake in Autolus Therapeutics by 195.0% in the 2nd quarter. Great Point Partners LLC now owns 3,441,667 shares of the company’s stock valued at $11,977,000 after acquiring an additional 2,275,000 shares during the period. Armistice Capital LLC increased its holdings in Autolus Therapeutics by 33.8% in the 2nd quarter. Armistice Capital LLC now owns 6,250,000 shares of the company’s stock worth $21,750,000 after acquiring an additional 1,578,000 shares in the last quarter. Finally, Affinity Asset Advisors LLC raised its position in Autolus Therapeutics by 27.4% during the second quarter. Affinity Asset Advisors LLC now owns 4,300,000 shares of the company’s stock worth $14,964,000 after acquiring an additional 925,000 shares during the period. 72.83% of the stock is owned by hedge funds and other institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.